How were Bellicum Pharmaceuticals' earnings last quarter?

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) issued its earnings results on Wednesday, August, 11th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($1.37) by $1.15. The biopharmaceutical company had revenue of $0.70 million for the quarter.

When did Bellicum Pharmaceuticals' stock split?

Bellicum Pharmaceuticals's stock reverse split on Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 5th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Bellicum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR) , Alliance Resource Partners (ARLP) , AVEO Pharmaceuticals (AVEO) , CyberArk Software (CYBR) , AcelRx Pharmaceuticals (ACRX) , Gilead Sciences (GILD) , Novavax (NVAX) , Pfizer (PFE) and Inovio Pharmaceuticals (INO) .

When did Bellicum Pharmaceuticals IPO?

Bellicum Pharmaceuticals (BLCM) raised $101 million in an initial public offering on Thursday, December 18th 2014. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray acted as the underwriters for the IPO and Trout Capital was co-manager.

NASDAQ:BLCM

Bellicum Pharmaceuticals (BLCM) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free BLCM Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $0.07
▼
$0.09
50-Day Range: $0.07
▼
$0.10
52-Week Range: $0.06
▼
$1.31

Volume: 6,000 shs
Average Volume: 22,874 shs
Market Capitalization: $727,056.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Earnings Ownership Social Media

Get Bellicum Pharmaceuticals alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Bellicum Pharmaceuticals Stock (NASDAQ:BLCM)

Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.

Ad Crypto 101 Media

SHOCKING Crypto Leak…

Claim your free seat by clicking here now.

BLCM Stock News Headlines

April 16, 2024 | americanbankingnews.com

Bellicum Pharmaceuticals (NASDAQ:BLCM) Share Price Crosses Above 50-Day Moving Average of $0.08

April 16, 2024 | americanbankingnews.com

Bellicum Pharmaceuticals (NASDAQ:BLCM) Receives New Coverage from Analysts at StockNews.com

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

February 22, 2024 | msn.com

Bellicum sells assets to MD Anderson, moves towards liquidation

January 25, 2024 | msn.com

Bellicum Pharmaceuticals Issues Super-Voting Share Privately

December 23, 2023 | morningstar.com

Bellicum Pharmaceuticals Inc BLCM

December 8, 2023 | benzinga.com

Bellicum Pharmaceuticals Stock (OTC:BLCM), Short Interest Report

October 27, 2023 | finance.yahoo.com

Futura Medical plc (FAMDF)

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

July 13, 2023 | finance.yahoo.com

BLCM - Bellicum Pharmaceuticals, Inc.

June 3, 2023 | fool.com

Bellicum Pharmaceuticals (NASDAQ: BLCM)

May 8, 2023 | investorplace.com

Why Is Bellicum Pharmaceuticals (BLCM) Stock Up 75% Today?

April 18, 2023 | msn.com

Why Digital Brands Group Shares Are Trading Lower By Over 15%; Here Are 20 Stocks Moving Premarket

April 18, 2023 | benzinga.com

Short Volatility Alert: Bellicum Pharma

March 15, 2023 | msn.com

BLCM Plummets on Stopping Trials of BPX-601 and BPX-603

March 15, 2023 | msn.com

Why Bellicum Pharmaceuticals (BLCM) Stock Is Down 48%

March 14, 2023 | finance.yahoo.com

Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives

February 24, 2023 | finance.yahoo.com

Why Bellicum Pharmaceuticals Stock Is Plunging Today

February 16, 2023 | finance.yahoo.com

Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposium

January 31, 2023 | finance.yahoo.com

CORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 19, 2023 | finance.yahoo.com

Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium

November 13, 2022 | finanznachrichten.de

Bellicum Pharmaceuticals, Inc.: Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational Update

November 10, 2022 | finance.yahoo.com

Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational Update

October 4, 2022 | finance.yahoo.com

Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the Mesa

September 15, 2022 | seekingalpha.com

BLCM Bellicum Pharmaceuticals, Inc.

September 1, 2022 | finance.yahoo.com

Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

August 25, 2022 | finance.yahoo.com

Bellicum Pharmaceuticals (BLCM) Could Find Support Soon, Here's Why You Should Buy the Stock Now

See More Headlines

Receive BLCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellicum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/11/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:BLCM
CUSIP: N/A
CIK: 1358403
Web: www.bellicum.com
Phone: (281) 454-3424
Fax: N/A
Employees: 13
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-24,970,000.00
Net Margins: N/A
Pretax Margin: -1,492.40%
Return on Equity: N/A
Return on Assets: -157.93%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.04
Quick Ratio: 3.04

Sales & Book Value

Annual Sales: $1.50 million
Price / Sales: 0.48
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.23 per share
Price / Book: 0.33

Miscellaneous

Outstanding Shares: 9,720,000
Free Float: 8,716,000
Market Cap: $727,056.00
Optionable: Not Optionable
Beta: 1.39

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Mr. David M. Maggio (Age 64)
Chief Executive Officer
Mr. Joseph Senesac (Age 54)
Senior Vice President of Technical Operations & Quality
Dr. Alan K. Smith Ph.D. (Age 66)
Chief Scientific Officer
Comp: $536.43k

Key Competitors

View All Competitors

BLCM Stock Analysis - Frequently Asked Questions

How were Bellicum Pharmaceuticals' earnings last quarter?: Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) issued its earnings results on Wednesday, August, 11th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($1.37) by $1.15. The biopharmaceutical company had revenue of $0.70 million for the quarter.
When did Bellicum Pharmaceuticals' stock split?: Bellicum Pharmaceuticals's stock reverse split on Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 5th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of Bellicum Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Alliance Resource Partners (ARLP), AVEO Pharmaceuticals (AVEO), CyberArk Software (CYBR), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Novavax (NVAX), Pfizer (PFE) and Inovio Pharmaceuticals (INO).
When did Bellicum Pharmaceuticals IPO?: Bellicum Pharmaceuticals (BLCM) raised $101 million in an initial public offering on Thursday, December 18th 2014. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray acted as the underwriters for the IPO and Trout Capital was co-manager.

This page (NASDAQ:BLCM) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Bellicum Pharmaceuticals (BLCM) Stock Price, News & Analysis

About Bellicum Pharmaceuticals Stock (NASDAQ:BLCM)

BLCM Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

BLCM Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info